This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Oraxol

Athenex, Inc.

Drug Names(s): HM30181A + paclitaxel, oral formulation of paclitaxel

Description: HM30181A is a P-glycoprotein pump inhibitor, (known for its effect in pumping drugs back to the gastrointestinal tract and thereby reducing drug absorption) which inhibits the pumping action of this protein and therefore, serves as an oral absorption enhancer.

Deal Structure: Hanmi and Kinex
In December 2011, Kinex Pharmaceuticals and Hanmi Pharmaceutical announced the execution of a license agreement from Hanmi Pharmaceuticals granting Kinex Pharmaceuticals exclusive rights to their Orascovery technology (which includes a non-absorbed compound that facilitates the absorption of compounds that are usually not orally bioavailable or absorbed) and their current lead products including an oral formulation of paclitaxel.

In October 2013, Kinex and Hanmi announced the execution of an agreement for Kinex Pharmaceuticals to lead the development of the Orascovery program in Malaysia, Thailand, Vietnam, the Philippines, and Indonesia.

In March 2015, Kinex Pharmaceuticals and Hanmi Pharmaceutical announced the execution of an agreement for Kinex Pharmaceuticals to lead the development of the Orascovery program in India. The addition of this territory is part of the strategic plan to support Kinex and Hanmis joint effort to execute a global...See full deal structure in Biomedtracker

Partners: Hanmi Pharmaceutical Co., Ltd. Zenith Technology Corporation PharmaEssentia Corporation


Oraxol News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug